ABC | Volume 114, Nº4, April 2020

Original Article Albuquerque et al. Ser49Gly Polymorphism in heart failure Arq Bras Cardiol. 2020; 114(4):613-615 Figure 1 – Distribution of number of deaths according to Ser49Glyβ1 genetic polymorphism. Data were expressed in absolute and relative frequencies. In the comparison of Ser-Ser x Ser-Gly x Gly-Gly genotypes: *p = 0.026, chi-square test. 54* (44,3%) 12* (23,5%) 1* (20,0%) Gly-Gly (n = 5) Ser-Gly (n = 52) Ser-Ser (n = 122) 60 50 30 40 20 10 0 Table 2 – Clinical outcomes according to the genetic polymorphisms of Ser49Gly β1-adrenergic receptor Clinical Variable * Total Ser49Gly β1 Genetic Polymorphism Ser-Ser (n = 122) Ser-Gly (n = 51) Gly-Gly (n = 5) p Final NYHA I 68 42 24 2 0.014 38.2% 34.4% 47.1% 40.0% II 57 45 9 3 32.0% 36.9% 17.6% 60.0% III 35 19 16 0 19.7% 15.6% 31.4% 0.0% IV 18 16 2 0 10.1% 13.1% 3.9% 0.0% Mean 2.02 ± 1.0 2.07 ± 1.0 1.92 ± 1.0 1.6 ± 0.5 0.420 Final LVEF (%) 35.4 ± 13.3 35.1 ± 13.2 35.8 ± 13.4 39.6 ± 16.2 0.751 Hospital admission n 74 54 18 2 0.55 % 41.6% 44.3% 35.3% 40.0% Death n 67 54 12 1 0.026 % 37.6% 44.3% 23.5% 20.0% Hospital admission + Death n 100 74 24 2 0.197 % 56.2% 60.7% 47.1% 40.0% *Numerical variables are expressed as mean ± standard deviation; categorical variables expressed as [n e (%)]. NYHA: New York Heart Association Functional Class; Table 3 – Multivariate Analysis: Predictors of death Variable p Odds ratio Copy of Gly allele 0.030 0.37 (0.15–0.91) Final NYHA 0.002 2.14 (1.32–3.45) Final LVEF 0.002 0.94 (0.91–0.98) Creatinine 0.051 1.52 (1.00–2.31) Low adherence 0.346 1.50 (0.65–3.46)) Final HR 0.124 1.03 (0.99–1.07) NYHA: New York Heart Association Functional Class; LVEF: left ventricular ejection fraction; HR: heart rate. 620